Immunocore Holdings plc
NASDAQ:IMCRBiotechnology
+$0.18 today
- Market cap
- $1.42B
- Beta
- 0.75
- P/E (TTM)
- -77.5
- EPS (TTM)
- -$0.37
Volume 0.30M
Average 0.40M
IMCR Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Immunocore Holdings plcNASDAQ: IMCR
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $1.78M (cash outflow) rose 496.7% year over year, ahead of the +15.4% change in trailing-twelve-month capital expenditures. Sequentially, it fell 38.3% from the prior quarter. Over 3 fiscal years it compounded at +13.6% a year.
Context
- Capital expenditures amounted to 1.1% of revenue in FY2025, down 1.0 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +496.7% holds above the trailing-twelve-month pace of +15.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
Mixed currencies · from the cash flow
- Latest · FY2025
- (3.23M) USD
- Year-over-year change
- +37.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.23M) | +37.6% |
| FY2024 | 2024-12-31 | (5.17M) | — |
| FY2023 | 2023-12-31 | (4.29M) | -94.9% |
| FY2022 | 2022-12-31 | (2.2M) | -58.9% |
| FY2021 | 2021-12-31 | (1.39M) | — |
Capital Expenditures vs competitors
How IMCR compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.4% is the 3rd highest of 10, against a peer median of -58.3%.
- Capital expenditures amounts to 1.5% of revenue for IMCR, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €218.49M EUR | -20.3% | -22.6% | 8.3% | |
| LTM Sep 2026 | $9.53M USD | +87.3% | -63.4% | 5.2% | |
| LTM Mar 2026 | $5.82M USD | +15.4% | +13.6% | 1.5% | |
| LTM Mar 2026 | €4.36M EUR | -58.3% | +0.4% | 11.7% | |
| LTM Jun 2026 | $2.47M USD | -62.7% | -58.3% | 2.4% | |
| LTM Mar 2026 | $1.73M USD | -37.7% | -19.2% | 1.1% | |
| LTM Jun 2026 | $1M USD | -66.7% | -30.7% | 0.9% | |
| LTM Mar 2026 | $945K USD | +77.3% | -45.5% | 4.4% | |
| FY2025 | €134.47K EUR | -65.6% | -50.7% | 4.8% | |
| FY2025 | A$45.77K AUD | -95.1% | +25.9% | 0.9% | |
| LTM Dec 2025 | $0 USD | — | -14.3% | 0.0% | |
| Peer median (excluding IMCR) | — | -58.3% | -26.7% | 3.4% | |
Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (180.03M) | (52.54M) | (34.32M) | (51.09M) | (26.42M) |
| Depreciation & Amortization | 7.59M | 5.34M | 3.24M | 4.2M | 2.43M |
| Deferred Income Tax | (12.69M) | (3.53M) | 0 | 0 | 11M |
| Stock-Based Compensation | 48.89M | 32.89M | 25.69M | 34.19M | 0 |
| Change in Working Capital | (21.96M) | (24.17M) | 4.58M | 45.13M | (6.92M) |
| Accounts Receivables | (4.86M) | (26.26M) | (14.14M) | (12.35M) | (5.46M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.47M | 4.91M | 2.08M | 7.27M | (1.83M) |
| Other Working Capital | (18.57M) | (2.81M) | 16.64M | 50.21M | 366K |
| Other Non-Cash Items | 15.09M | (7.19M) | 3.14M | (6.38M) | 11.94M |
| Operating Cash Flow | (143.11M) | (49.21M) | 2.33M | 26.06M | (7.97M) |
| Capital Expenditures | (1.39M) | (2.2M) | (4.29M) | (5.17M) | (3.23M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (350M) | (22.32M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 13.39M |
| Other Investing Activities | 106K | 6K | (925.46K) | 44K | 0 |
| Investing Cash Flow | (1.28M) | (2.2M) | (4.29M) | (355.13M) | (12.16M) |
| Debt Repayment | 0 | 0 | 0 | 352.5M | 0 |
| Common Stock Issued | 286.89M | 139.52M | 0 | 6.8M | 9.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3M | 5.93M | 27.18M | (15.42M) | 0 |
| Financing Cash Flow | 288.19M | 145.44M | 27.18M | 343.88M | 9.2M |
| Effect of Forex Changes | 625K | (12.65M) | 6.56M | (1.71M) | 19.81M |
| Net Change in Cash | 144.42M | 81.39M | 31.78M | 13.11M | 8.89M |
| Free Cash Flow | (144.49M) | (51.41M) | (1.97M) | 20.89M | (11.2M) |
Immunocore Holdings plc
NASDAQ:IMCR
Intrinsic Alpha fair value
Locked
Current Price
$27.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.